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Abstract
A clinically-related animal model of Parkinson’s disease (PD) may enable the elucidation of the etiology of the disease and
assist the development of medications. However, none of the current neurotoxin-based models recapitulates the main
clinical features of the disease or the pathological hallmarks, such as dopamine (DA) neuron specificity of degeneration and
Lewy body formation, which limits the use of these models in PD research. To overcome these limitations, we developed a
rat model by stereotaxically (ST) infusing small doses of the mitochondrial complex-I inhibitor, rotenone, into two brain
sites: the right ventral tegmental area and the substantia nigra. Four weeks after ST rotenone administration, tyrosine
hydroxylase (TH) immunoreactivity in the infusion side decreased by 43.7%, in contrast to a 75.8% decrease observed in rats
treated systemically with rotenone (SYS). The rotenone infusion also reduced the DA content, the glutathione and
superoxide dismutase activities, and induced alpha-synuclein expression, when compared to the contralateral side. This ST
model displays neither peripheral toxicity or mortality and has a high success rate. This rotenone-based ST model thus
recapitulates the slow and specific loss of DA neurons and better mimics the clinical features of idiopathic PD, representing
a reliable and more clinically-related model for PD research.
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Introduction
PD is a common, neurodegenerative disorder characterized by
tremor at rest, rigidity, bradykinesia, hypokinesia, and postural
instability. Its pathological hallmarks include the loss of DA
neurons of the substantia nigra-striatum system and the presence
of proteinacious cytoplasmic inclusions, known as Lewy bodies, in
the remaining DA neurons[1]. Although PD has been studied
intensively for almost two centuries, since James Parkinson gave
the first detailed description of the disease in 1817[2], the etiology
and pathogenesis of the disease remain unknown.
A well-established and clinically-related model is needed
urgently to enable the study of PD pathogenesis and to facilitate
the search for effective treatments for PD. PC12[3,4,5], SH-
SY5Y[6,7] cells, and primary dissociated midbrain DA cells[8]
have been extensively used as PD cell models. Because the
microenvironment of in vitro cultured cells is substantially different
from that of the living brain tissues, the value of cell models is
limited. Therefore, increasing attention has been paid to animal
models of PD. So far, there are two kinds of animal models of PD:
traditional neurotoxin models and genetic mouse models. The
genetic models of PD, established by inducing mutations
associated with familial forms of PD, are of limited value because
most of the murine genetic models do not display the characteristic
loss of DA neurons observed in PD, as they are still at an early
stage of this disease. Moreover, it has been reported that,
collectively, these genetic mutations are found in less than 10%
of PD patients in the US[9].
The two most popular neurotoxin-based models of PD are
generated by the administration of 6-hydroxydopamine (6-OHDA)
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The
intracerebral infusion of 6-OHDA in mice, rats, cats, and non-
human primates produces a rapid loss of dopaminergic terminals and
dopaminergic neurons, which results in an anterograde degenera-
tion of the entire nigrostriatal dopaminergic system [10,11,12,13].
However, alpha-synuclein expression is not found in these models
[14]. As mitochondrial complex I deficiency was found to be a
major factor responsible for neurodegeneration[15], and since
Parkinson-like symptoms were found in drug (one of the main
components is MPTP) addicts[16], MPTP, a potent inhibitor of
complex I, has extensively been used to induce Parkinsonian
symptoms in animals (mice, cats, and primates). However, these
models do not have the chronic progression and extensive
pathological involvement (such as serotoninergic and norepine-
phrinergic pathways) seen in PD [17,18].
Like MPTP, rotenone is another complex I inhibitor and has
been reported to possess highly selective toxicity on DA neurons
in vitro[5,19] and in vivo[15,20]. The main differences between
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7878MPTP and rotenone are that rotenone facilitates the for-
mation of alpha-synuclein fibrils[15] and easily crosses the blood
brain barrier, as well as the cell membrane, because of its
lipophilic nature; MPTP requires enzymatic conversion into
MPP
+ whose entry into neurons needs a dopamine transporter.
Among the various animal models of PD, the rotenone model has
recently drawn particular attention for two reasons: 1) it
reproduces most of the motor symptoms and the histopatholog-
ical features of PD, including Lewy bodies[21,22], and 2)
rotenone and other pesticides are powerful inhibitors of
mitochondrial respiration, and recent epidemiological studies
suggest an association of these toxic compounds with the higher
incidence of sporadic Parkinsonism among the population of
rural areas[23,24].
Nevertheless, systemic administration of rotenone can cause
peripheral toxicity, and the behavioral changes of animals might
be the result of general health problems rather than a specific
motor deficit characteristic of PD symptoms[25]. Recently, several
researchers intracerebrally infused rotenone into the medial
forebrain bundle (MFB) [26,27] or into the substantia nigra pars
compacta (SNc) [28] and reproduced neurochemical and
neuropathological features of hemiparkinsonism in rats, but these
models failed to reproduce the extensive pathological involvement
seen in PD. Moreover, alpha-synuclein expression in the DA
neurons was not mentioned in these studies [28,29].
It is widely acknowledged that it is not only the substantia nigra
and striatum, but also other regions of brain that are responsible
for PD [17]. Among these brain regions, the ventral tegmental
area (VTA), which contains abundant DA neurons, is remarkably
important for the pathogenesis of PD [30,31]. It has even been
reported that VTA lesions are responsible for the hypokinesia of
PD [32]. In this study, rotenone was directly infused stereotaxically
into the right VTA and SNc of rats. Four weeks after the infusion,
the behavioral profiles, biogenic amine levels in the striatum,
oxidative stress levels, and TH immunoreactivities were assessed.
More importantly, compared to the SYS model, the ST model was
further validated by the detection of alpha-synuclein expression
and the ultrastructural changes in SNc.
Materials and Methods
Animals
The experiments described in this paper were approved by the
Ethical Committee on Animal Experimentation of Tongji
Medical College, Huazhong University of Science and Technol-
ogy, China. Inbred adult female Sprague-Dawley rats (220–
260 g, from the Center of Experimental Animals, Tongji
Medical College, Huazhong University of Science and Technol-
ogy, China) were used. The animals were maintained under
standard conditions with 12-hour light/dark cycles and 2262uC
and 6065% humidity. They had access to standard laboratory
chow and acidified water ad libitum. Rats were randomly assigned
to five groups: ST infusion of rotenone at 3 mgi n1mlD M S O
(3-mgg r o u p ,n = 4 0 ) ,6mgi n1mlD M S O( 6 - mg group, n=15),
12 mgi n1ml DMSO (12-mgg r o u p ,n=1 5 ) ,S Ti n f u s i o no f1ml
DMSO (vehicle group) (n=15), or SYS infusion of rotenone at
2 mg/kg/day (n=12). The total period of the study was six
months, and no accidental animal deaths took place during the
study. For dose-response studies of the DA and 5-HT contents
and the oxidative stress level in the ST model, animals from the
3-, 6- and 12-mg groups were sacrificed on the fourth week
following the ST infusion of rotenone. For the time-response
studies, animals from the 3-mg group were sacrificed on the
second, fourth, sixth, and eighth weeks after surgery.
Drugs and Chemicals
The rotenone, apomorphine (APO), DA, serotonin (5-HT),
chloral hydrate, 3,39-diaminobenzidine, hematoxylin, and Hoechst
33258 were purchased from Sigma (St. Louis, MO); Triton-X100,
paraformaldehyde, dimethyl sulfoxide (DMSO), and EDTA were
from Amresco (Solon, OH); rabbit anti-tyrosine hydroxylase
polyclonal antibody and mouse anti-a-synuclein antibody were
obtained from Santa Cruz (Santa Cruz, CA); biotinylated goat-anti-
rabbit IgG, peroxidase-conjugated streptavidin, superoxide dismu-
tase (SOD) activity colorimetric assay kit, and glutathione (GSH)
colorimetric detection kit were from Abcam (Cambridge, MA);
Cy3-conjugated goat-anti-rabbit IgG and FITC-conjugated don-
key-anti-mouse IgG were purchased from Proteintech (Chicago,
IL); and the malondialdehyde (MDA) colorimetric Assay Kit was
from Oxis International (Beverly Hills, CA, USA). Sodium dodecyl
sulfate (SDS) and other reagents were of analytical grade and
procured locally. For the high performance liquid chromatography
(HPLC) experiments, double-distilled water was filtered and
deionized by using a Milli-Q system (Waters, Milford, MA).
Rotenone Infusion
For ST infusion, the animals were anesthetized with chloral
hydrate (400 mg/kg in 0.9% NaCl, I.P.) and fastened on a cotton
bed over a stereotaxic frame (RWD Life Science, Shenzhen,
China). Rotenone dissolved in DMSO was infused into the right
VTA (AP: 5.0 mm; L: 1.0 mm; DV: 7.8 mm) at a flow rate of
0.2 ml/min. The needle was left in place for additional five minutes
for complete diffusion of the drug. Rotenone was infused into the
right SNc (AP: 5.0 mm; L: 2.0 mm; DV: 8.0 mm) at a flow rate of
0.2 ml/min, with a five-minute needle retention. After needle
withdrawal, proper postoperative care was given until the animals
recovered completely. The animals were given ibuprofen and
penicillin in their drinking water for 24 hours to alleviate potential
postsurgical discomfort and to prevent infection. For the SYS
infusion, rotenone dissolved in sunflower oil was injected
subcutaneously (2 mg/kg/d) into the back of these rats daily for
four weeks.
Spontaneous Rotation Behavior
Rats receiving ST infusion were intensively observed for any
abnormal activity during the first 72 hours. One of the striking
features following recovery from anesthesia was spontaneous
circling. The animals were kept in a transparent cage following
surgery, and the spontaneous rotations in the cage were counted
over a period of one hour.
APO-Induced Rotations
ST infusion rats were evaluated for APO-induced rotations from
the second week after rotenone administration and tested every
week in the first month, every two weeks in the next two months,
andthen every monthfora total ofsix months.Theratswereplaced
on a table (1 m61 m) with a railing, allowed to acclimate to the
environment for 10 minutes, and then administered an intraper-
itoneal injection of APO (1.5 mg/kg). Subsequent rotational
behavior was then recorded for 30 minutes. Followingthe rotational
testing, the animals were put back into their cages.
DA and 5-HT Determination
The left and right striata were micro-punched from the brains,
and the tissues were weighed wet. The tissues were immediately
frozen and stored at 280uC until sonication in ice-cold 0.01 M
HClO4 solution containing 0.01% EDTA [33,34]. The superna-
tant (12,000 rpm for 10 minutes) was collected and injected (20 ml)
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MA). The Lichrosorb Column (C18, 10 mm, 25 cm64.6 mm,
Waters, MA) was employed, and the mobile phase consisted of
trisodium citrate (0.02 M), sodium dihydrogen phosphate (0.05 M),
methanol (40%), EDTA (0.028 g/L), and SDS (0.15 g/L). The
solution was adjusted to pH 3.0 with 98% H2SO4,f i l t e r e d
through a 0.45-mm membrane, and degassed. The flow rate was
set to 1.0 ml/min, and the column temperature was set at 40uC.
After separation, DA and 5-HT were detected at the excitation
wavelength of 280 nm and an emission wavelength of 315 nm.
GSH and SOD Activity and MDA Level Determination
Animals were sacrificed, and the brains were washed with ice-
cold 0.01 M sterilized phosphate buffered solution (PBS). The left
and right midbrains were micro-punched and cut into small pieces
and placed into glass bottles. The tissue pieces were then
homogenized in ice-cold PBS by mechanical trituration. The
homogenate was centrifuged at 3000 rpm for 10 minutes, and a
supernatant was obtained, which was used for the determination of
the GSH and SOD activity. All procedures were performed at 4uC
and icepacks were used to maintain the temperature during the
homogenization. The spectrophotometric assay for GSH involved
oxidation of GSH by the sulfhydryl reagent 5,59-dithio-bis(2-
nitrobenzoic acid) to form the yellow derivative 59-thio-2-nitroben-
zoic acid, measurable at 412 nm[35]. The principle of the SOD
activity determination is based on the inhibition of nitroblue
tetrasolium reduction by the xanthine-xanthine oxidase system
serving as a superoxide radical generator[36]. The SOD activity
was expressed as units per mg tissue protein (U/mg protein). The
MDA levels were analyzed using a method based on the reaction
with thiobarbituric acid at 90-100uC. In the thiobarbituric acid test,
MDA or MDA-like substances and thiobarbituric acid were mixed
to allow reaction to produce a pink pigment with a maximum
absorption at l=532 nm. The protein concentration was deter-
mined by the bicinchoninic acid method.
Immunohistostaining
Coronal sections (5-mm) were cut through the striatum (at
1.2 mm caudal to the bregma) and the SNc (from 24.5 to
26.2 mm caudal to the bregma) by using a sledge microtome
(Wetzlar, Germany). The sections were de-waxed, hydrated, and
the endogenous peroxidase was quenched with 0.3% H2O2 for 30
minutes. After antigen retrieval, the slides were treated with 0.5%
Triton-X100 for 30 minutes and 5% bovine serum albumin (BSA)
for 30 minutes. The sections were first incubated with antibody/
PBS (TH antibody, 1:100 dilution) for 48 hours at 4uC and then
incubated with the secondary biotinylated goat anti-rabbit IgG for
60 minutes and with peroxidase-conjugated streptavidin for 45
minutes. The immunoreactions were visualized by 3,39-diamino-
benzidine for 15-20 minutes. The slides from the anterior to
posterior regions of the left and right striata were densitometrically
observed and analyzed by employing the Image-Pro plus 6.0
software package. A design-based, unbiased, stereological method
and a morphometry/image analysis system has been previously
described for counting TH-positive cells[37]. In each section, the
region of interest was outlined (SNc and VTA), and the TH-
positive cells/mm
2 in that region were selected and semiautomat-
ically counted. For the double immunohistostaining, the sections
were incubated with both antibodies/PBS (TH antibody, 1:100
dilution and alpha-synuclein, 1:100 dilution) for 48 hours at 4uC
and then with Cy3-conjugated goat-anti-rabbit IgG (1:100) and
FITC-conjugated donkey-anti-mouse IgG (1:100) diluted by
10 mg/ml Hoechst 33258 (the secondary antibody). The slides
were then observed under a confocal fluorescence microscope and
the pictures were still analyzed by Image-Pro plus 6.0.
Ultrastructure of the SNc
Rats were deeply anesthetized on the first, second, third, and
fourth week after operation and perfused through the aorta with
ice-cold PBS and then with paraformaldehyde (4% wt/vol) and
glutaraldehyde (1% wt/vol) in PBS[38]. The brains were post-
fixed in 2.5% glutaraldehyde at 4uC for 6 hours after the
separation. A 1-mm
3 tissue block from the left and right SNc
regions (24.5 to 26.2 mm caudal to the bregma) was micro-
punched, fixed in PBS containing 2.5% glutaraldehyde, and
preserved at 4uC for further processing. The fragments were post-
fixed in 1% osmium tetroxide in the same buffer, dehydrated in
graded alcohols, embedded in Epon 812, sectioned with an
ultramicrotome, and stained with uranyl acetate and lead citrate.
The sections were then examined under a transmission electron
microscope (TEM; Technai 10, Philips, Netherlands).
Pathology of the Peripheral Organs
The pathological evaluation of the peripheral organs was
performed on eight rats from each group. Four weeks after the
rotenone treatment, the animals were deeply anesthetized and
perfused through the aorta with ice-cold PBS and then with
paraformaldehyde (4% wt/vol) in PBS. The heart, kidney, liver, lung,
spleen, and stomach were taken out and immersed in 4%
paraformaldehyde in PBS at 4uC for 24 hours before paraffin-
embedding. The tissue sections were cut into 5-mm pieces, stained with
hematoxylin and eosin (HE), and examined under a light microscope.
Statistical Analyses
The statistical analyses were carried out using SPSS version 12.0
for Windows (SPSS, Chicago, IL, USA). Because all groups
showed a normal distribution, the intergroup differences were
assessed using parametric statistical methods, paired independent
sample t-tests and a one-way analysis of variance (ANOVA). The
results are presented as the means6SD. The P value considered
statistically significant was P,0.05.
Results
Variability and Mortality
All the ST model rats showed typical behavioral features of PD,
such as back hunching and stiffness, face-washing behaviors,
bradykinesia, or hypokinesia. Ten of the twelve SYS models
developed characteristic behavioral features of PD after rotenone
infusion for four weeks. The remaining two rats developed the
behavioral features after another four-week SYS infusion of
rotenone. No animals died accidentally throughout the study.
Spontaneous Rotation Behavior after Recovery from
Anesthesia
After recovery from anesthesia, spontaneous rotations to the
opposite side of the infusion site were observed in all the rats
receiving infusions of rotenone into the VTA and SNc. The
frequency of spontaneous rotations was 224652 times per hour
during the first day after surgery. This behavior showed no
significant difference between the dose-response groups. The
intensity of the behavior persisted for about 24 hours, gradually
declined thereafter, and vanished after 48–72 hours.
APO-Induced Rotations Advanced Gradually
ST-infused rats demonstrated typical contralateral rotations
following APO injections at all time points. The rotational
Rotenone Model for PD
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the rotational behavior was dose-dependent in the 3-, 6-, and 12-
mg groups. In the 3-mg group, 30 minutes after the APO
administration, the rotation number was 115621, 149622,
181616, 225621, 249621, and 268621 at the first, second,
third, fourth, sixth, and eighth week, respectively, and the change
was time-dependent (Figure 1). The total number of rotations
increased gradually until the twenty-fourth week (330635).
DA Is Depleted in the Early Stage, but 5-HT Is Decreased
in the Late Stage
The levels of monoamine neurotransmitters in the left and right
striata of rat brains were not significantly different in the control
groups. However, the unilateral intracerebral infusion of rotenone
at doses of 3, 6, and 12 mg caused significant DA depletion in the
ipsilateral striatum in a dose-dependent fashion at the fourth week
as compared to the contralateral striatum. For instance, the DA
content in the 3-, 6-, and 12-mg groups were reduced to 24.42%,
17.38%, and 13.11% at the fourth week, respectively (Figure 2A).
In 3- and 6-mg groups, the 5-HT content did not show any change,
but in the 12-mg group, 5-HT was decreased (Figure 2C). For the
time-dependence study, there appeared to be a progressive loss of
DA in the striatum. At the second, fourth, sixth, and eighth weeks,
the DA content was decreased by 57.73%, 75.58%, 76.43%, and
82.68% as compared to the contralateral striata, respectively
(Figure 2B). The 5-HT content did not exhibit any significant
change during the first six weeks, but it decreased at the eighth
week (Figure 2D).
GSH and SOD Decreased and MDA Generated in Dose-
and Time-Dependent Fashions
Four weeks after surgery, the ST infusion of rotenone caused a
significant increase in the MDA level and a decrease in GSH and
SOD activity in the ipsilateral midbrain as compared to the
contralateral side. The vehicle infused midbrain did not
experience any change in the MDA level and GSH or SOD
activity as compared to the contralateral side. The ST infusion of
rotenone at doses of 3, 6, and 12 mg into rats resulted in a
significant depletion of GSH and SOD (Figure 3A and 3C) and a
generation of MDA in a dose-dependent manner (Figure 3E). The
GSH in the ipsilateral midbrain on the fourth week was reduced
by 44.03%, 57.54%, and 66.23% in the 3-, 6-, and 12-mg groups,
respectively, as compared to the contralateral side; the SOD in the
ipsilateral midbrain on the fourth week was decreased by 26.64%,
36.49%, and 42.39%, respectively; and the MDA was increased by
86.55%, 131.53%, and 152.44%, respectively. The GSH activity
in the ipsilateral midbrain on the second, fourth, sixth, and eighth
weeks after infusion was diminished by 34.88%, 44.03%, 52.49%,
and 57.62%, respectively (Figure 3B); the SOD activity was
decreased by 22.35%, 26.64%, 29.46%, and 35.13%, respectively,
while the MDA levels were increased by 64.93%, 86.55%,
124.28%, and 122.36%, respectively(Figures 3D and 3F),
indicating a slow and time-dependent change in these three
oxidative stress markers.
Nigrostriatal TH Immunoreactivity Decreased and Alpha-
Synuclein Expression Increased
The histological examination of the brain tissues from the rats
indicated that the vehicle infusion did not change the intensity of
the TH immunostaining in the striatum (Figure 4G–H), while the
TH staining intensity was significantly decreased (by 66.4%) in rats
infused with rotenone (Figure 4I–J). The number of TH-positive
neurons was decreased in the ipsilateral VTA and SNc as
compared to the contralateral side. The finding was further
confirmed by HE staining of VTA and SNc (Figure 4A). The
death rates of the TH-positive cells in the VTA and SNc were
28.72% and 58.53%, respectively, as compared to the contralat-
eral side in 3-mg group, while the death rates was 33.47% and
73.73% in the 12-mg group. The double immunohistostaining of
alpha-synuclein and TH showed a dose-dependent decrease in the
number of TH-positive neurons, an increase in alpha-synuclein
expression in the lesioned brain (Figure 5). The quantitative
analysis indicated that alpha-synuclein expression in the SNc was
up-regulated by 156.1% in 12-mg group as compared to 3-mg
group (Figure 5E, I and Figure 4L), while the TH immunoreac-
tivities in the lesioned SNc were decreased by 38.6% and 77.3% as
compared to the contralateral SNc (Figure 5B, F, J and Figure 4L).
Abnormal Mitochondria Associated with DA Neuron
Degeneration
The left and right SNc (from 24.5 to 26.2 mm caudal to the
bregma) of the SYS group and the 3-mg group were micro-
punched and examined under a transmission electron microscope.
No conspicuous ultrastructural changes were found in the
contralateral SNc (Figure 6A–B), where as mitochondrial swelling,
mitochondrial crest fracture, mitochondrial vacuolar degenera-
Figure 1. Differential effect of APO on the ST infusion rats. The APO-induced rotations were counted on the 1
st,2
nd,3
rd,4
th,6
th,8
th,1 0
th,1 2
th,
16
th,2 0
th, and 24
th weeks following the 3-mg rotenone infusion and on the 2
nd,3
rd,4
th,6
th, and 8
th weeks following the 6-mg and 12-mg rotenone
infusions. The control animals did not exhibit rotations. The total number of rotations is expressed as the mean6SD (n=6).
doi:10.1371/journal.pone.0007878.g001
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ribosomes from rough endoplasmic reticula, lipofuscin deposition,
and perinuclear space augmentation were observed in neurons of
lesioned SNc (Figure 6C–J). Occasionally, the rough endoplasmic
reticula were dilated, and lysosomes were increased in glial cells
(Figure 6H).
Peripheral Organs Alterations in the SYS Model
Among the 12 SYS-infused rats, no animals died spontaneously
within four weeks of the systemic rotenone administration
(2.0 mg/kg/day). In these SYS rats, significant changes were
observed in the liver, kidney, lung, and spleen, while there were no
obvious changes in the heart and stomach. For the ST models, no
changes were found in the peripheral organs of the 3-, 6-, and 12-
mg groups up to the fourth week. In the SYS models, neutrophilic
exudates were detected in the lung (Figure 7B), while the alveolar
walls of the ST infusion rats were thin and delicate (Figure 7A). In
the liver, the central veins of hepatic lobules were fractured in the
SYS models (Figure 7D), but they were intact in the ST models
(Figure 7C). In the kidney, the number of red blood cells was
increased in the renal glomeruli (Figure 7F) and renal medulla
(Figure 7I), while few red blood cells were seen in the renal
glomeruli of ST animals (Figure 7E and Figure H). In the spleen,
hemorrhage and hemosiderin deposition were observed in the
SYS infusion rats (Figure 7K), while white pulp was noted in the
spleen (Figure 7J). The SYS infusion of rotenone exerted little
influence on the heart (Figure 7M) and stomach (Figure 7L) of the
SYS infusion rats.
Discussion
Currently available neurotoxin-based models failed to repro-
duce the progressive nature and the extensive pathological
involvement in PD. Moreover, these models are of limited value
due to some significant limitations, such as a rapid loss of DA
neurons, a failure to induce typical brain lesions, an absence of
alpha-synuclein expression, and the potential of systemic toxicity.
Furthermore, most of the current genetic murine models are in the
early-stage of PD and fail to demonstrate the characteristic loss of
dopaminergic cells observed in PD. In this study, we developed rat
PD models by ST and SYS administration of rotenone and made
comparisons between these two models. We examined behaviors,
brain histology, peripheral toxicity, biogenic amine levels in the
striatum, the ultrastructural changes of the SNc, and the oxidative
stress levels of the midbrain. In summary, the main features of our
current model include: 1) a one-time, low-dose ST infusion of
rotenone could generate a characteristic decrease in the
nigrostriatal TH immunoreactivity; 2) APO-induced rotations
progressed gradually until the 24
th week; 3) rotenone depleted DA,
but not 5-HT at the beginning in the low-dose groups; 4) the GSH
and SOD activities were lowered, and the generation of MDA was
increased in the midbrain treated with rotenone; 5) alpha-
synuclein expression was increased, and TH-positive neurons
were decreased, both in a dose-dependent fashion; 6) the infused
SNc developed characteristic ultrastructural changes of abnormal
mitochondria; 7) the SYS model can reproduce the typical
behaviors of PD but is associated with peripheral toxicity; and 8)
after rotenone infusion for four weeks, all the ST model rats and
Figure 2. Changes in striatal levels of DA and 5-HT after rotenone infusion. For the dose-response (3-, 6-, 12-mg groups) studies, the
animals were sacrificed at the fourth week following the ST infusion of rotenone, and the (A) DA and (C) 5-HT contents were measured.
For the time-response studies, the animals were infused with 3 mg of rotenone and sacrificed on the second, fourth, sixth, and eighth week (B
and D). The results are expressed in ng/mg (wet tissue), and the data were given as the mean6SD (n=6). *P,0.05 as compared to contralateral
side.
doi:10.1371/journal.pone.0007878.g002
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features of PD. No animals accidentally died during the study.
These results demonstrate that acute stereotaxical administration
of a small dose of rotenone can induce long-lasting neurochemical
and neuropathological PD-like changes in the nigrostriatal system.
ST Model
Spontaneous contralateral rotation following intracerebral
administration of MPP
+ [39] or ferrous citrate[40] under the
same situation has been reported in rats. Recent studies have
shown that spontaneous rotation can be induced by intra-nigra
infusion of the rotenone, but not by intra-MFB infusion of
rotenone. The rotation might be caused by the release of DA into
the ipsilateral striatum after rotenone infusion[29]. The sponta-
neous rotational behavior can also serve as a measure for assessing
the success of the animal model. The result of the APO-induced
contralateral rotations was different from a previous study in
which the infusion of rotenone into the SNc alone caused
ipsilateral rotations. The difference might be due to intact VTA
neurons in the intra-nigra models. On the other hand, the APO
injection at the fourth week following the rotenone infusion failed
to produce any significant stereotypical circling behavior in MFB-
lesioned rats [29], which makes it difficult to assess the model in
the early stage. Moreover, according to previous studies which
indicated APO-induced rotations in PD rats should be over 210 in
the first 30 minutes [12,28,29,37], we speculated that four weeks
Figure 3. Effects of ST infusion of rotenone on SNc oxidative stress levels. (1) Dose response: the rats were sacrificed on the fourth week
following the ST infusion of different doses (3-, 6-, or 12-mg) of rotenone, and the GSH activity (Figure 3A), SOD activity (Figure 3C), and MDA level (E)
in the midbrain on the left and right sides were spectrophotometrically measured. (2) Time response: The animals infused with 3-mg rotenone were
sacrificed on the second, fourth, sixth, and eighth week for the GSH, SOD, and MDA determination. *P,0.05, as compared to contralateral side. Data
were expressed as the means6SD (n=6).
doi:10.1371/journal.pone.0007878.g003
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nigrostriatal TH immunoreactivity.
The HPLC analysis of the DA and 5-HT contents suggested
that rotenone selectively and specifically acts on the dopaminergic,
but not on the serotonergic system; this finding was also seen in an
earlier study [28]. Significantly decreased 5-HT contents in the
striatum by high-dose rotenone or long-term low-dose rotenone
should contribute to extensive pathological involvement in the
serotonergic system seen in idiopathic PD[17], which is respon-
sible for the non-motor symptoms including depression [18].
Another important finding about the GSH and SOD activity and
MDA level, which is similar to previous results [41,42,43], is that
specific effects of rotenone on the electron transport chain could
cause an increase in oxygen free radicals, thereby resulting in
oxidative stress and ultimately leading to severe damage of the DA
neurons.
Since the pathological changes in these models included both a
loss of the TH-positive neurons and a decrease in the TH
expression in the lesioned side, we not only counted the number of
TH-positive cells but also measured the integrated intensity of
both sides of the VTA and SNc. The finding that the death rate of
TH-positive cells in the VTA was substantially lower than that in
the SNc is yet another piece of evidence that the DA neurons in
the VTA are more resistant to damage and is consistent with
previous studies [44,45]. In SYS models, the most interesting
finding was the asymmetric loss of TH-positive neurons in the two
sides of the brain, which is very close to the unilateral onset of
human idiopathic PD. Moreover, the double-immunohistostaining
study suggested that rotenone-induced alpha-synuclein expression
was increased in a dose-dependent manner.
Previous animal studies on PD seldom dealt with the
ultrastructural changes of the SNc. In this study, the most
Figure 4. Effect of rotenone on the striatum, VTA, and SNc TH immunoreactivity. Pictures of the TH immunostaining of coronal sections
were taken at the level of the striatum from the DMSO- or rotenone-infused rats (3-mg group) four weeks after infusion. Each treatment group had
four rats. The left striatum represents the intact side of the brain, and the right striatum represents the lesioned side of the same animal. The TH
immunoreactivity on the ipsilateral side of the striatum was decreased by 66.4% (Figure 4I–J; *P,0.05, as compared to the contralateral side). The
ST-infused rats (3- and 12-mg groups) and SYS models were sacrificed four weeks after the rotenone infusion, and coronal sections were HE-stained
and immunohistochemically stained with TH. HE-staining showed a significant decrease in the number of neurons in the VTA and SNc (A, 3 mg
group). The number of TH-positive neurons (E) was decreased by 43.7% (B), 53.6% (C), 59.0%, and 75.8% (D) in the right side of the 3- and 12-mgS T
models and in the left and right sides of SYS models, respectively, as compared to the contralateral side of the ST models. The integrated intensity of
the VTA and SNc was decreased by 38.1%, 54.5%, 46.4%, and 95.3% in the right side of the 3- and 12-mg ST models and in the left and right sides of
the SYS models, respectively (F) (*P,0.05, as compared with the contralateral side; #P,0.05, as compared with the lesioned side of 3-mg group; and
P,0.05, as compared with the other side of the SYS group) (Scale bars=50 mm).
doi:10.1371/journal.pone.0007878.g004
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swelling and crest fracture, as found in the SYS model. The
ultrastructural change in the lysosome system was another
important finding. It is acknowledged that the autophagy-lysosome
pathway plays a pivotal role in the pathogenesis of many
neurodegenerative disorders including PD[46]. Lysosomes remove
the damaged mitochondria by means of phagocytosis, forming
autophagosomes. The rough endoplasmic reticula were dilated
and lysosomes were increased in even glial cells, suggesting that
glial cells may be involved in the pathogenesis of PD, which may
provide us with a therapeutic alternative for PD[12].
SYS Model
In 2000, it was first reported that, similar to the action of
MPTP, chronic systemic rotenone exposure reproduced features
of PD[15]. Since then, research efforts have been directed at
rotenone-induced PD, and the results have been encouraging. The
rotenone-induced PD animal model reproduces most motor
symptoms and the histopathological changes of PD including
Lewy bodies [20,21,22]. In contrast, the validity of rotenone-
induced PD symptoms has been challenged by some researchers
[25,26]. However, our previous research showed that subcutane-
ously infused rotenone was an effective method to reproduce PD
in rats [20]. In SYS models, a progressive loss of body weight (by
2–5 g/d, data not shown) and yellow discoloration of the skin were
also observed. These changes might have been caused by difficulty
in eating and skin-cleaning associated with behavioral changes.
Two rats did not develop the behavioral features after the four-
week rotenone SYS infusion, but their body weight decreased
gradually (by 2–5 g/d). After treatment with SYS-infused
rotenone for another four weeks, they developed behavioral
changes. We found that rotenone could accumulate in the
subcutaneous adipose tissue because of its lipophilic nature, which
might, in part, explain the variation in susceptibility among the
animals. When the animals lose body weight, rotenone is released
from the fatty tissues and then enters body fluid circulation,
thereby causing systemic toxicity, which may be responsible for the
high death rate of the SYS models. The significant pathological
changes observed in the peripheral organs of SYS models were
different from previously reported findings with Lewis rats [26], in
Figure 5. Double immunohistostaining of alpha-synuclein and TH. Samples of the double immunohistostained alpha-synuclein and TH of
the lesioned SNc were taken from the rats sacrificed four weeks after surgery (3-mg group: A–H; 12-mg group: I–L). Alpha-synuclein was visualized by
FITC-conjugated donkey-anti-mouse IgG, TH was labeled by the Cy3-conjugated goat-anti-rabbit IgG, and the nucleus was stained by the Hoechst
33258. The last graph of the three rows was obtained by the overlapping the first three graphs (Scale bars=50 mm). Compared with the contralateral
side of the ST models (A-D), a dose-dependent increase in alpha-synuclein expression in the lesioned brain and a decrease in the number of
TH-positive neurons are shown in E–H (3-mg group) and I–L (12-mg group). The quantitative data were shown as Figure 4L.
doi:10.1371/journal.pone.0007878.g005
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7878Figure 6. Ultrastructural changes of the SNc. The ultrastructural changes of the SNc were set in order: (1)mitochondrial swelling, (2)mitochondrial crest
fracture, (3)mitochondrial vacuolar degeneration, (4)dilated and broken rough endoplasmic reticula, (5)liberation of ribosomes from the rough endoplasmic
reticula, (6)lipofuscin deposition, (7)perinuclear space augmentation. A and B: normal mitochondria, rough endoplasmic reticulum. and ribosomesi nt h e
contralateral SNc of the 3-mg group animals one week or four weeks after surgery; C: (1), (2), (4) and (5) in lesioned SNc of the 3-mg group animals one week
a f t e rs u r g e r y ;D :( 1 ) ,( 2 )a n d( 3 )i nt h el e s i o n e dS N co ft h e3 - mg group animals two weeks after surgery; E: (1), (2), (2), (4) and (5) in the lesioned SNc of the 3-mg
group animals three weeks after surgery; F: (6) in the lesioned SNc of the 3-mgg r o u pa n i m a l so n ew e e ka f t e rs u r g e r y ;G :( 1 ) ,( 2 ) ,( 3 )a n d( 7 )i nt h el e s i o n e dS N c
of the 3-mg group animals four weeks after surgery; H: the rough endoplasmic reticula and increased lysosomes in glial cells of lesioned SNc of 3-mgg r o u p
animals four weeks after surgery; I and J: (1), (2) and (3) in both sides of the SNc of the SYS model four weeks after rotenone administration.
doi:10.1371/journal.pone.0007878.g006
Figure 7. Pathological changes in peripheral organs in Parkinsonian rats. A: The alveolar walls of the ST infusion rats were thin and delicate;
B: neutrophilic exudates were detected in the pulmonary alveoli; C: the normal hepatic lobules and central veins; D: the central vein of the hepatic
lobule was fractured in SYS rats; E and H: the normal renal glomerulus and renal medulla; F and I: Red blood cells were increased in the renal
glomeruli and renal medulla; J: the normal white pulp of the spleen; K: hemorrhage and hemosiderin deposition in the spleen of the SYS rats; L and
M: normal heart and stomach of SYS rats (Scale bars=50 mm).
doi:10.1371/journal.pone.0007878.g007
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might be due to the fact the Sprague-Dawley rats had stronger
survival ability, and different chows were used.
The most commonly used 6-OHDA and MPTP models are
generally acute and can produce a rapid loss in terminals and a
decrease in TH-positive cells [21]. Moreover, 6-OHDA and
MPTP are very difficult to store and must be used immediately
after being dissolved. The ST model can definitely reproduce slow
and specific nigrostriatal dopaminergic degeneration in association
with the formation of Lewy bodies and the progression in APO-
induced rotational behavior, which so far has not been found with
6-OHDA models and only reported once with MPTP models [47].
We came to the conclusion that the Parkinsonian animal model
produced by ST infusion of rotenone into both the VTA and SNc
is effective for the study of the behavioral syndromes, the
molecular mechanism of Lewy body formation, and the link
between this formation and nigrostriatal dopaminergic neuronal
degeneration. It can also be used for the screening of anti-
Parkinsonian drugs and the development of novel therapeutic and
diagnostic methods. Currently, we are using this model for
neuroprotective drug screening and stem cell therapy for PD.
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